Keros Therapeutics (KROS) Stock Forecast & Price Target

Compare

358 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KROS Analyst Ratings

Moderate Buy

3 Buy

4 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Keros

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KROS Stock 12 Month Forecast

Average Price Target

$21.00

▲(0.82% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Keros Therapeutics in the last 3 months. The average price target is $21.00 with a high forecast of $27.00 and a low forecast of $16.00. The average price target represents a 0.82% change from the last price of $20.83.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","57":"$57","20.25":"$20.3","32.5":"$32.5","44.75":"$44.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$27.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,20.25,32.5,44.75,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.18,17.935384615384613,18.69076923076923,19.446153846153845,20.201538461538462,20.956923076923076,21.712307692307693,22.467692307692307,23.223076923076924,23.978461538461538,24.733846153846155,25.48923076923077,26.244615384615386,{"y":27,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.18,17.473846153846154,17.767692307692307,18.06153846153846,18.355384615384615,18.64923076923077,18.943076923076923,19.236923076923077,19.53076923076923,19.824615384615385,20.11846153846154,20.412307692307692,20.706153846153846,{"y":21,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.18,17.08923076923077,16.998461538461537,16.907692307692308,16.816923076923075,16.726153846153846,16.635384615384616,16.544615384615383,16.453846153846154,16.363076923076925,16.27230769230769,16.181538461538462,16.09076923076923,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":56.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.28,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.18,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$27.00

Average Price Target$21.00

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jason Zemansky

Bank of America Securities

$18→$19

Hold

-8.79%

Downside

Reiterated

11/28/25

Keros Therapeutics (KROS) Gets a Hold from Bank of America Securities

Andreas Argyrides

Oppenheimer

$23→$27

Buy

29.62%

Upside

Reiterated

11/12/25

Keros Therapeutics (KROS) Gets a Buy from Oppenheimer

Benjamin Burnett

Wells Fargo

$26→$23

Buy

10.42%

Upside

Reiterated

11/11/25

Keros Therapeutics (KROS) Receives a Buy from Wells FargoShifting Our Focus to KER-065 in DMD (3Q25 Update)

Andres Y. Maldonado

H.C. Wainwright

$20

Buy

-3.98%

Downside

Reiterated

11/06/25

Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key PartnershipsHence, we reiterate our Buy rating and $20 PT.

Matt Phipps

William Blair

―

Hold

―

Reiterated

11/06/25

Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties

Yun Zhong

Wedbush

$15→$16

Hold

-23.19%

Downside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: Staar Surgical (NASDAQ: STAA), Keros Therapeutics (NASDAQ: KROS) and Electrocore (NASDAQ: ECOR)WE maintain our Neutral rating on KROS while we continue to await clarity on KER-065 in DMD, and we raise our PT from $15 to $16 after model adjustments

Tyler Van Buren

TD Cowen

―

Hold

―

Reiterated

11/05/25

Keros Therapeutics: Strategic Focus on KER-065 and Financial Position Justifies Hold Rating

Thomas Smith

Leerink Partners

$35

Buy

68.03%

Upside

Reiterated

08/07/25

Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics

Greg Harrison

Scotiabank

$26

Buy

24.82%

Upside

Reiterated

06/10/25

Keros Therapeutics (KROS) Receives a Buy from Scotiabank

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

05/30/25

Truist Financial Sticks to Their Buy Rating for Keros Therapeutics (KROS)

Vamil Divan

Guggenheim

―

Hold

―

Reiterated

05/29/25

Guggenheim Sticks to Their Hold Rating for Keros Therapeutics (KROS)

Prakhar Agrawal

Cantor Fitzgerald

―

Hold

―

Downgraded

01/21/25

Keros Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldKeros Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Joseph Catanzaro

Mizuho Securities

$40→$15

Buy

-27.99%

Downside

Reiterated

01/17/25

Keros Therapeutics (KROS) Gets a Buy from Piper Sandler

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jason Zemansky

Bank of America Securities

$18→$19

Hold

-8.79%

Downside

Reiterated

11/28/25

Keros Therapeutics (KROS) Gets a Hold from Bank of America Securities

Andreas Argyrides

Oppenheimer

$23→$27

Buy

29.62%

Upside

Reiterated

11/12/25

Keros Therapeutics (KROS) Gets a Buy from Oppenheimer

Benjamin Burnett

Wells Fargo

$26→$23

Buy

10.42%

Upside

Reiterated

11/11/25

Keros Therapeutics (KROS) Receives a Buy from Wells FargoShifting Our Focus to KER-065 in DMD (3Q25 Update)

Andres Y. Maldonado

H.C. Wainwright

$20

Buy

-3.98%

Downside

Reiterated

11/06/25

Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key PartnershipsHence, we reiterate our Buy rating and $20 PT.

Matt Phipps

William Blair

―

Hold

―

Reiterated

11/06/25

Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties

Yun Zhong

Wedbush

$15→$16

Hold

-23.19%

Downside

Reiterated

11/06/25

Tyler Van Buren

TD Cowen

―

Hold

―

Reiterated

11/05/25

Keros Therapeutics: Strategic Focus on KER-065 and Financial Position Justifies Hold Rating

Thomas Smith

Leerink Partners

$35

Buy

68.03%

Upside

Reiterated

08/07/25

Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics

Greg Harrison

Scotiabank

$26

Buy

24.82%

Upside

Reiterated

06/10/25

Keros Therapeutics (KROS) Receives a Buy from Scotiabank

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

05/30/25

Truist Financial Sticks to Their Buy Rating for Keros Therapeutics (KROS)

Vamil Divan

Guggenheim

―

Hold

―

Reiterated

05/29/25

Guggenheim Sticks to Their Hold Rating for Keros Therapeutics (KROS)

Prakhar Agrawal

Cantor Fitzgerald

―

Hold

―

Downgraded

01/21/25

Keros Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldKeros Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Joseph Catanzaro

Mizuho Securities

$40→$15

Buy

-27.99%

Downside

Reiterated

01/17/25

Keros Therapeutics (KROS) Gets a Buy from Piper Sandler

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Keros Therapeutics

1 Month

xxx

Success Rate

16/26 ratings generated profit

Average Return

+3.97%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +3.97% per trade.

3 Months

xxx

Success Rate

16/26 ratings generated profit

Average Return

+13.07%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +13.07% per trade.

1 Year

Srikripa DevarakondaTruist Financial

Success Rate

9/16 ratings generated profit

Average Return

+0.62%

reiterated a buy rating 7 months ago

Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +0.62% per trade.

2 Years

xxx

Success Rate

9/26 ratings generated profit

Average Return

-18.13%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 34.62% of your transactions generating a profit, with an average return of -18.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KROS Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KROS has received 7 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. KROS average Analyst price target in the past 3 months is 21.00.

Each month's total comprises the sum of three months' worth of ratings.

KROS Financial Forecast

KROS Earnings Forecast

Next quarter’s earnings estimate for KROS is -$0.70 with a range of -$1.60 to -$0.48. The previous quarter’s EPS was -$0.18. KROS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year KROS has Performed in-line its overall industry.

KROS Sales Forecast

Next quarter’s sales forecast for KROS is $2.76M with a range of $0.00 to $10.00M. The previous quarter’s sales results were $14.26M. KROS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year KROS has Performed in-line its overall industry.

KROS Stock Forecast FAQ

What is KROS’s average 12-month price target, according to analysts?

Based on analyst ratings, Keros Therapeutics’s 12-month average price target is 21.00.

What is KROS’s upside potential, based on the analysts’ average price target?

Keros Therapeutics has 0.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KROS a Buy, Sell or Hold?

Keros Therapeutics has a consensus rating of Moderate Buy which is based on 3 buy ratings, 4 hold ratings and 0 sell ratings.

What is Keros Therapeutics’s price target?

The average price target for Keros Therapeutics is 21.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $27.00 ,the lowest forecast is $16.00. The average price target represents 0.82% Increase from the current price of $20.83.

What do analysts say about Keros Therapeutics?

Keros Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of KROS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Keros Therapeutics (KROS) Stock Forecast & Price Target

KROS Analyst Ratings

KROS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Keros Therapeutics

KROS Analyst Recommendation Trends

KROS Financial Forecast

KROS Earnings Forecast

KROS Sales Forecast

KROS Stock Forecast FAQ

Detailed List of Analyst Forecasts